Ajim Tamboli, CFA joined ADARx in July 2024 as our Chief Financial Officer, with over 25 years of combined experience in the biotechnology industry in operations, investment management, and investment banking. Prior to ADARx, Mr. Tamboli was the CFO at Arbor Biotechnologies and preceding that CFO at Monte Rosa Therapeutics, where he was responsible for leading private and public fund raises of over $465M, including an upsized $255M IPO. He previously served as the CFO of Rodin Therapeutics, where he ran investor fundraising and supported their successful acquisition by Alkermes. Mr. Tamboli has extensive experience in healthcare asset management, having managed a global portfolio of biotech and pharmaceutical companies, notably as a founding partner of Endurant Capital Management and with Columbia Management. Earlier in his career, Mr. Tamboli was a Senior Biotechnology Equity Research Analyst with Lehman Brothers and additional investment banks. Mr. Tamboli received his MS in Biotechnology and BS in Biomedical Science/Entrepreneurial Management from the University of Pennsylvania School of Engineering and Applied Science/Wharton School, where he was a Benjamin Franklin Scholar. He is a CFA® charterholder.
